GlobeNewswire

ALLDATA Joins the ADPA in Its Mission to Ensure Fair Access to Automotive Data and Information

Del

ALLDATA engages in advocating access to technical information and in paving the way for independent data publishers serving the European automotive aftermarket

ELK GROVE, Calif., Jan. 07, 2019 (GLOBE NEWSWIRE) -- ALLDATA Europe GmbH, an affiliate of ALLDATA LLC, an AutoZone company, has joined the European Automotive Data Publishers Association (ADPA) to help drive legislation that will allow publishers to provide innovative, technological, multi-brand solutions to the aftermarket. 

As an ADPA member, ALLDATA joins many leading organizations in Europe seeking access to automotive data and information. With over 30 years of business in the United States, ALLDATA has a legacy of being an innovative data solution provider and of helping workshops to be their most successful – a track-record the company aims to replicate with its customers in Europe.

“We are pleased to align with the ADPA and work alongside other distinguished industry players whose mission is to provide solutions to aftermarket workshops, so they may deliver diagnostic and repair services to their customers that meet quality manufacturer standards,” said Kevin F. Culmo, Managing Director ALLDATA Europe GmbH and Group Vice President, ALLDATA LLC. “Our goal is to collaborate with the original equipment manufacturers (OEMs) in Europe as we have done successfully in the U.S. to ensure the sustainability of independent workshops and garages across Europe.”

ADPA President Ralf Pelkmann added, “It is proof that ADPA is seen as the right forum for independent automotive data publishers to join forces to take care of important issues impacting their business.”

ALLDATA has provided ALLDATA Repair® to more than 6,500 customers in the European market since it launched at Automechanika in 2014. Today, ALLDATA Repair contains 22 brands covering more than 850 models and 37 million articles of detailed procedures and diagrams.

About ALLDATA
ALLDATA® is the leading provider of unedited OEM (original equipment manufacturer) information for the automotive repair and collision industries. Founded in 1986, the Elk Grove, Calif.-based company has more than 115,000 subscribers worldwide who rely on ALLDATA for OEM-accurate automotive service and collision repair information, shop management software, training, and customer relations tools.

ALLDATA’S flagship products, ALLDATA Repair® and ALLDATA Collision®, feature a factory-direct database of more than 38,000 engine-specific vehicles – 95% of all vehicles on the road today. ALLDATA Repair is the go-to source for comprehensive, factory-correct mechanical information for the automotive industry, and it includes expert repair technician support in ALLDATA® CommunitySM. ALLDATA Collision is the single source of OEM collision repair information, delivering unedited and regularly updated information for structural repairs, mechanical, and diagnostic information. ALLDATA DiagnosticsTM is the company’s newest product – it turns a tablet into an affordable, professional scan tool with the power of ALLDATA built in. ALLDATA Collision Advantage bundles ALLDATA Collision with Estimate Integration to deliver OE-accurate estimates, including Vital repairs and OEM-required inspections and repairs. The ALLDATA Mobile® app, combined with a tablet, makes vehicle information and ALLDATA Repair available right at the vehicle to speed repairs. ALLDATA Manage® Online is a comprehensive shop management system that offers anytime, anywhere access to create quotes and invoices, electronically order parts, manage bays and technicians and track shop profitability. ALLDATA Tech-Assist® provides one-on-one assistance by phone from ASE Certified Master Technicians to help diagnose and solve tough repairs. ALLDATA® Training GarageSM is an online training resource with technical and business courses for shop staff and automotive students at all levels. Visit www.alldata.com for more information.

About AutoZone (NYSE:AZO)
As of November 17, 2018, AutoZone sells auto and light truck parts, chemicals, and accessories through 5,631 stores in 50 states in the U.S., the District of Columbia, and Puerto Rico, 567 stores in Mexico, and 20 stores in Brazil for a total count of 6,218.

AutoZone is the leading retailer and a leading distributor of automotive replacement parts and accessories in the United States. Each AutoZone store carries an extensive product line for cars, sport utility vehicles, vans and light trucks, including new and remanufactured automotive hard parts, maintenance items, accessories and non-automotive products. Many stores also have a commercial sales program that provides commercial credit and prompt delivery of parts and other products to local, regional and national repair garages, dealers, service stations and public sector accounts. AutoZone also sells the ALLDATA brand diagnostic and repair software through www.alldata.com. Additionally, we sell automotive hard parts, maintenance items, accessories and non-automotive products through www.autozone.com and our commercial customers can make purchases through www.autozonepro.com. AutoZone does not derive revenue from automotive repair or installation.

Media Contacts:

ALLDATA Europe GmbH
Julia Hilger
+49-221-534107-0
Julia.Hilger@alldata.com
AutoZone Media Contact
Jennifer Q. Hughes
901.495.7043
Jennifer.hughes@autozone.com

ALLDATA Media Contact

Sheryl Bussard
916.478.3105
sheryl.bussard@alldata.com

AutoZone Financial Contact

Brian Campbell
901.495.7005
brian.campbell@autozone.com


Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

WillScot to Participate at the Barclays Industrial Select Conference16.1.2019 21:00Pressemelding

BALTIMORE, Jan. 16, 2019 (GLOBE NEWSWIRE) -- WillScot Corporation (“WillScot”)(NASDAQ: WSC), the specialty rental services market leader providing innovative modular space and portable storage solutions across North America, today announced that Brad Soultz, President and Chief Executive Officer, and Tim Boswell, Chief Financial Officer, will present at the Barclays Industrial Select Conference at the Loews Miami Beach Hotel in Miami, Florida, on Wednesday, Feb. 20, 2019. The presentation will take place at 10:20 a.m. EST. About Williams Scotsman Headquartered in Baltimore, Maryland, WillScot Corporation is the public holding company for the WillScot family of companies in the United States, Canada and Mexico. WillScot Corporation trades on the NASDAQ stock exchange under the ticker symbol “WSC.” WillScot is the specialty rental services market leader providing innovative modular space and portable storage solutions across North America. It is the modular space supplier of choice for t

CCI has been retained by Waterloo Brewing to obtain Cannabis Licence16.1.2019 16:00Pressemelding

TORONTO, Jan. 16, 2019 (GLOBE NEWSWIRE) -- Cannabis Compliance Inc., (CCI) of Toronto, Ontario is pleased to announce they have partnered with Waterloo Brewing to help them obtain their Research and standard Processing Licence to develop cannabis-infused beverages. “CCI is working with Waterloo Brewing on the early stages of the application process and we are confident that we will help them achieve their desired licenses in time to be an active player in this growing sector of the cannabis industry”, said Brian Wagner, CEO and Founder, Cannabis Compliance Inc. “We are here to guide our clients through the early stages of the licensing process and for the many Health Canada requirements thereafter.” CCI offers end to end business solutions for cannabis companies large and small. Our team brings with them years of experience in the quality, regulatory, security and cultivation sectors, and supports manufacturers and retailers through regulatory challenges. As the world’s largest and mos

Aryaka Announces Expansion of Senior Leadership Team with New Chief Revenue Officer, Chief Transformation Officer and Chief Marketing Officer16.1.2019 15:00Pressemelding

Karen Freitag, Michelle Owczarzak, & Shashi Kiran join Aryaka to address significant growth and assist global enterprises in adopting managed connectivity as-a-service SAN MATEO, Calif., Jan. 16, 2019 (GLOBE NEWSWIRE) -- Aryaka®, announced today the appointment of several new executive hires to the company’s leadership team, including Karen Freitag (Chief Revenue Officer), Michelle Owczarzak (Chief Transformation Officer), and Shashi Kiran (Chief Marketing Officer). “Connectivity is the lifeblood of the global enterprise and Aryaka is the industry benchmark for secure managed connectivity worldwide. We are excited to have experienced industry veterans join our robust executive leadership team and continue to help build upon the immense success and growth that Aryaka has seen in recent years,” said Matt Carter, CEO of Aryaka. “As our customers expand globally, embrace SD-WAN, or move to the cloud, we’re becoming the de facto choice for their needs to make this happen better, faster, che

ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-601 in Advanced Solid Tumors16.1.2019 07:00Pressemelding

Pyrrolobenzodiazepine-based antibody drug conjugate targets AXL, a receptor tyrosine kinase highly expressed in solid tumors LAUSANNE, Switzerland, Jan. 16, 2019 (GLOBE NEWSWIRE) -- ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that the first patient has been dosed in its Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics and anti-tumor activity of ADCT-601 in patients with selected solid tumors that are locally advanced or metastatic. ADCT-601 is an ADC composed of a humanized monoclonal antibody against human AXL, conjugated using GlycoConnect™ site specific conjugation technology to a pyrrolobenzodiazepine (PBD) dimer toxin. In preclinical studies, ADCT-601 demonstrated potent and specific in vitro and in vivo anti-tumor activity in multiple cancer-derived models with different levels of AXL expression, and was stable and well tolerated

GSA Europe’s Managing Director Elected Co-lead of CEN’s TC456 Committee15.1.2019 21:12Pressemelding

SAN GWANN, Malta, Jan. 15, 2019 (GLOBE NEWSWIRE) -- GSA Europe’s Managing Director Mark Pace has been elected by the Comité Européen de Normalisation (CEN) to lead the creation of a European Union online gaming reporting standard. CEN has established Technical Committee 456 to create this standard in support of online gambling supervision. GSA Europe joined Technical Committee 456 as a Liaison Organization in 2017. The Technical Committee’s mandate from the European Commission is directly aligned with work that GSA Europe has already started, namely, to create a single standard set of data elements and single standard way in which data is provided by online gambling providers to EU Member State regulatory authorities. In addition to joining and now leading the Technical Committee’s work, GSA Europe also donated their draft Regulatory Data Set and Regulatory Reporting Interface to CEN seeking to help jump-start the Committee’s work. “Joining CEN’s TC456 as a Liaison Organization, and no

Orion Biotechnology Reports Positive Results for Colorectal Cancer in Preclinical Study15.1.2019 15:00Pressemelding

OTTAWA, Jan. 15, 2019 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a developer of novel medical treatments, today announced preclinical data produced in collaboration with Charles River Laboratories, evaluating the efficacy of OB-002O (5P12-RANTES) in colorectal cancer. BALB/c mice were inoculated subcutaneously with the CT-26 colorectal cancer cell line. Three days after inoculation intraperitoneal treatment was started with OB-002O, a murine anti-PD-1 antibody, OB-002 + anti-PD-1, or saline placebo. Treatment was given daily or every third day. Treatment with OB-0020 alone led to statistically significant delayed tumor growth at multiple time-points. An even more profound effect on the decrease in mean tumor volume was observed in combination cohort where animals received both, OB-0020 and the anti-PD-1 antibody (p>0.05). “There is growing awareness of the role of CCR5 antagonism as an important component of cancer immunotherapy. OB-002O is an extremely potent CCR5 antagonist